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BACKGROUND: An increased knowledge regarding the predictors of rebleeding after endoscopic therapy for
bleeding ulcers should improve clinical management and outcomes. The aim of this systematic
review was to identify the strongest and most consistent predictors of rebleeding to assist in the
development of tools to stratify and appropriately manage patients after endoscopic therapy.
METHODS: Bibliographic database searches for prospective studies assessing rebleeding after endoscopic
therapy for bleeding ulcers were performed. Relevant studies were identified, and data were
abstracted in a duplicate and independent fashion. The primary outcomes sought were significant
independent predictors of rebleeding by multivariable analyses in ≥2 studies.
RESULTS: Ten articles met the prespecified inclusion criteria. The pooled rate of rebleeding after endoscopic
therapy was 16.4%. The independent pre-endoscopic predictors of rebleeding were hemodynamic
instability (significant in 5 of 5 studies; summary odds ratio [OR] 2.75, 95% confidence interval [CI]
1.99–3.51) and comorbid illness (significant in 2 of 7 studies; insufficient data to calculate
summary OR or report OR range). The independent endoscopic predictors of rebleeding were active
bleeding at endoscopy (significant in 5 of 8 studies; summary OR 1.93, 95% CI 1.30–2.55), large
ulcer size (significant in 4 of 5 studies; summary OR 2.01, 95% CI 1.21–2.80), posterior duodenal
ulcer (significant in 2 of 3 studies; insufficient data to calculate summary OR or report OR range),
and lesser gastric curvature ulcer (significant in 2 of 2 studies; insufficient data to calculate
summary OR or report OR range).
CONCLUSIONS: The independent predictors of recurrent hemorrhage after endoscopic therapy, particularly those
that are the strongest and most consistent in the literature, may be used to select patients who are
most likely to benefit from aggressive post-hemostasis care, including intensive care unit (ICU)
observation and second-look endoscopy. Prospective studies designed to formally assess the relative
utilities of these factors in predicting rebleeding and dictating management are needed.
(Am J Gastroenterol 2008;103:2625–2632)
INTRODUCTION
Acute upper gastrointestinal bleeding (UGIB) is a serious
clinical problem that accounts for over 300,000 hospitaliza-
tions in the United States annually (1) and has a mortality rate
of ∼5–10% (2–4). Bleeding peptic ulcer is the most com-
mon cause of UGIB (5). Endoscopic hemostatic therapy is
the treatment of choice for patients with high-risk bleeding
peptic ulcers as it has been shown to significantly reduce
To access a continuing medical education exam for this article, please visit
www.acg.gi.org/journalcme.
rebleeding and improve survival in this patient population
(6, 7). Initial hemostasis can be achieved in over 90% of pa-
tients, although approximately 20% will experience clinically
relevant rebleeding.
As recurrent hemorrhage is probably the most important
predictor of death from UGIB (8, 9) and influences other
important end points such as transfusion requirement, need
for surgery, and length of hospital stay, identifying patients
who are likely to rebleed is a critical component of effectively
managing patients with bleeding peptic ulcers. Triaging these
patients to higher levels of care and managing them more
aggressively may improve clinical outcomes.
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Multiple prospective clinical trials have evaluated the risk
factors for rebleeding after endoscopic hemostasis (10–21).
In this systematic review, we summarize these predictors of
rebleeding in a clinically relevant fashion. The goals of this
review are to identify the most consistent and powerful pre-
dictors of rebleeding after endoscopic hemostasis, to suggest
how these risk factors can be utilized in the risk stratification
process, and to propose future directions in research pertain-
ing to this topic.
METHODS
The systematic review was conducted according to standard
guidelines (22). A computer-assisted search with the OVID
(Ovid Technologies, Inc. New York, NY) interface to Med-
line and Embase was conducted to identify potentially rel-
evant articles. A search of these databases from January 1,
1950 to January 1, 2008, was performed using the exploded
(exp) medical subject heading (MESH) terms: “exp peptic ul-
cer hemorrhage” AND “exp risk assessment” OR “exp risk”
OR “exp risk factors.” Manual searches of reference lists
from potentially relevant articles were performed to identify
any additional studies that may have been missed using the
computer-assisted strategy.
Two investigators (BJE, SY) independently reviewed ti-
tles and abstracts of all citations identified by the literature
search. Potentially relevant studies were retrieved, and se-
lection criteria were applied. The selection criteria were: (a)
articles that evaluated predictors of rebleeding after endo-
scopic hemostatic therapy with a multivariate analysis, (b)
studies in which data were collected prospectively, (c) stud-
ies in humans, (d) studies published in the English language,
and (e) data not duplicated in another manuscript. Eligible
articles were reviewed, and data were abstracted onto stan-
dardized data extraction forms in a duplicate and independent
manner by two investigators (BJE, SY). The following data
were abstracted for each included study: (a) date and loca-
tion of the trial, (b) demographics of the study population,
(c) definition of UGIB, (d) definition of rebleeding, (e) sub-
ject inclusion criteria, (f) subject exclusion criteria, (g) use
of pharmacotherapy, (h) use of endoscopic hemostatic ther-
apy, (i) number and proportion of patients achieving initial
hemostasis, (j) number and proportion of patients experienc-
ing rebleeding, (k) death rate, (l) predictors of rebleeding in
a univariate analysis, (m) predictors of rebleeding in a multi-
variable analysis, (n) predictive value of each individual risk
factor, and (o) risk factors that were found not to predict re-
bleeding. The agreement between the investigators was over
90%. Any discrepancies were resolved by consensus.
The methodological quality of each included study was
assessed by one investigator (BJE) using the criteria set forth
by the Third U.S. Preventive Services Task Force for cohort
studies (23). These criteria rate the internal validity of a study
as “good” (all criteria met), “fair” (not all criteria met, but
no fatal flaws), or “poor” (fatal flaw in at least one of the
criteria).
The following data are presented in the results section: (a)
the clinical trials meeting the inclusion criteria, (b) the char-
acteristics of each included trial, (c) composite rebleeding
and death rates for the entire data set, (d) studied risk fac-
tors that did not predict recurrent bleeding by a multivariable
analysis, and (e) independent predictors of recurrent hemor-
rhage with their odds ratios (OR) and confidence intervals
(CI) (when available).
For predictors that were independently significant in two
or more trials, the number of trials in which the predictor
was positive is compared with the number of trials in which
it was assessed but reported to be not significant. Further,
the numbers and proportions of patients with each risk factor
who suffered rebleeding are compared with the numbers and
proportion of patients without the risk factor who rebled.
A weighted summary OR for recurrent hemorrhage for
each predictor that was significant in two or more studies
was calculated by a meta-analysis of the ORs and standard
errors (calculated from the 95% CIs for the OR) provided in
individual studies (Review Manager software, version 4.2.7;
Cochrane Collaboration, Oxford, United Kingdom). These
summary effect estimates should be interpreted with cau-
tion, however, because included studies generally did not re-
port ORs for factors that were not significant predictors in the
multivariable analysis. Therefore, a comprehensive summary
estimate, including data from both positive and negative stud-
ies, could not be calculated, and the summary estimates may
overestimate the potential risk.
RESULTS
A total of 304 titles were initially reviewed. Of these, 27
abstracts appeared pertinent, but the review of text resulted
in 10 articles that met the criteria for this systematic review
(11–20).
As per the inclusion criteria, all articles evaluated risk fac-
tors for rebleeding after endoscopic therapy as a primary end
point. Seven of these clinical trials evaluated risk factors for
overall failure of endoscopic therapy, which included both
the failure to achieve initial hemostasis as well as recurrent
hemorrhage. In these studies, however, initial hemostasis was
achieved in over 90% of patients, making recurrent hemor-
rhage the dominant end point in the statistical analyses. The
remaining three studies exclusively addressed risk factors
for rebleeding after endoscopic hemostasis had been initially
achieved. Whenever possible, results are presented to reflect
rebleeding after initial hemostasis. If these data were unavail-
able, then the results indicate overall failure of hemostasis,
rather than recurrent hemorrhage per se. The baseline pa-
tient characteristics, follow-up data, and clinical outcomes
were collected prospectively in all included trials. It is not
stated, however, in any of the studies whether the study de-
sign for the evaluation of prognostic factors predicting re-
bleeding was determined a priori. Eight studies assessed the
predictors of rebleeding by a univariate analysis followed by
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Table 1. Prospective Clinical Trials Evaluating Risk Factors for Recurrent Hemorrhage After Endoscopic Hemostatic Therapy
Mean Age,
First Author and Year Location % Female Pharmacotherapy Endotherapy





Epinephrine and 1% polidocanol
Wong 2002 Hong Kong 62.5 yr, 30.5 Omeprazole PO Epinephrine and heater probe
Chung 2001 Korea 55.2 yr, 13.3 Ranitidine IV Hemoclip or hypertonic saline-epinephrine
injection or both
Thomopolous 2001 Greece 58.6 yr, 19.7 Ranitidine IV Epinephrine
Brullet 1996 (gastric ulcers) Spain 65.9 yr, 32 Ranitidine IV,
followed by PO
Epinephrine and 1% polidocanol
Brullet 1996 (duodenal ulcers) Spain 61.7 yr, 22 Ranitidine IV,
followed by PO
Epinephrine and 1% polidocanol
Park 1994 U.K. 64 yr, 41.7 Ranitidine IV Epinephrine




Epinephrine and 5% ethanol or heater probe
Villanueva 1993 Spain 64.9 yr, 34 Ranitidine IV or PO Epinephrine and polidocanol or epinephrine and
thrombin
Saeed 1993 U.S. 61.8 yr, 0 Ranitidine IV,
followed by PO
Epinephrine and 97% ethanol or epinephrine and
heater probe
IV = intravenous; PO = oral.
a multivariate analysis, while two studies utilized the multi-
variate analysis alone. All studies were assessed as “good”
or “fair” according to the US Preventive Services Task Force
criteria for controlled cohort studies.
The specific characteristics of each clinical trial are listed
in Table 1. Oral proton pump inhibitor (PPI) therapy was
used in two studies: after intravenous (IV) histamine 2 re-
ceptor antagonist (H2RA) infusion in one study (11) and as
a monotherapy in the other (13). H2RA therapy was used in
nine studies (12, 14–20), followed by oral PPI in one study
(11). None of the included studies report the use of “optimal”
medical therapy involving an IV bolus of PPI followed by con-
tinuous infusion. Endoscopic hemostasis was achieved using
a variety of techniques. Epinephrine injection monotherapy
was administered in two studies (12, 18) and in one arm
of another study (14). Epinephrine in combination with a
second hemostatic method was administered in six studies
(11, 13, 15, 16, 19, 20) and in one arm of two other trials
(14, 17).
When pooling data from all the clinical trials, successful
initial hemostasis was achieved in 92.3% of patients. Re-
current hemorrhage occurred in 16.4%. The pooled overall
mortality was 6.4%, although the length of follow-up varied
among studies from 72 h to 1 month.
The risk factors that independently predict rebleeding after
endoscopic therapy based on the multivariable analyses in
each included clinical trial are listed in Table 2. The ORs and
CIs (when available) of risk factors that are significant in at
least two studies are listed in Table 3, according to the study.
The independent pre-endoscopic predictors of rebleeding
identified in multiple clinical trials are the presence of hemo-
dynamic instability (significant in 5 of 5 studies; summary
OR 2.75, 95% CI 1.99–3.51) and comorbid illness (significant
in 2 of 7 studies; insufficient data to calculate summary OR
or report OR range). The independent endoscopic predictors
of rebleeding identified in multiple clinical trials are active
bleeding at endoscopy (significant in 5 of 8 studies; summary
OR 1.93, 95% CI 1.30–2.55), large ulcer size (significant in
4 of 5 studies: >2 cm [3 of 4 studies], >1 cm [1 of 1 study];
summary OR 2.01, 95% CI 1.21–2.80), posterior duodenal
wall ulcer (significant in 2 of 3 studies; insufficient data to
calculate summary OR; OR range 2.06–2.48), and lesser gas-
tric curvature ulcer (significant in 2 of 2 studies; insufficient
data to calculate summary OR or report OR range).
As endoscopic therapy with epinephrine alone is less ef-
fective than epinephrine followed by a second modality,
we identified the independent predictors identified in the
two trials that employed epinephrine monotherapy. The pre-
endoscopic predictors were shock, the use of nonsteroidal
anti-inflammatory drugs (NSAIDs), history of ulcer bleed, an
elevated heart rate, and obesity, while the endoscopic predic-
tors were active bleeding and posterior duodenal, duodenal
bulb, and lesser curve of stomach locations. The only pre-
dictors from these two studies not identified in other studies
were the use of NSAIDs and obesity.
The number of studies in which each of the identified pre-
dictors was significant compared with the number of studies
in which the predictors did not reach statistical significance is
illustrated in Table 4. In addition, for each study in which the
aforementioned predictors were significant, the number and
percentage of patients with each predictor who experienced
rebleeding, the number and percentage of patients without the
predictor who experienced rebleeding, as well as the overall
number and proportion of patients who rebled in the study
are listed in Table 5.
Table 6 lists the risk factors that were not found to be inde-
pendently predictive of recurrent hemorrhage in more than
one study. These risk factors include, age, sex, anticoagulant
or NSAID use, hematemesis, and pre-endoscopy transfusion
requirement.
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Table 2. Results of Prospective Clinical Trials Evaluating Risk Factors for Recurrent Hemorrhage After Endoscopic Hemostatic Therapy
No. of No. of
Patients Patients
Total No. With Initial With Independent Risk Factors for Rebleeding
First Author and Year of Patients Hemostasis Rebleeding From Multivariable Analyses
Guglielmi 2002 447 429 (95.9%) 86 (20%) Pre-endoscopic: systolic blood pressure ≤100, cirrhosis,
recent surgery
Endoscopic: Forrest 1a–2c (active or recent bleeding),
ulcer >2 cm, location fundus, location body
Wong 2002 1,144 1,128 (98.6%) 94 (8.2%) Pre-endoscopic: shock, hemoglobin <10 g/dL
Endoscopic: Fresh blood in stomach, active bleeding,
ulcer ≥2 cm
Chung 2001 143 139 (94.4%) 36 (25.2%) Endoscopic: active spurting
Thomopolous 2001∗ 427 390 (91.3%) 86 (20%) Pre-endoscopic: shock, use of NSAIDs, history of ulcer
bleed
Endoscopic: active bleeding, location posterior duodenum
Brullet 1996 (gastric ulcers) 178 175 (98.3%) 41 (23.4%) Endoscopic: active bleeding, location high on lesser curve
of stomach, ulcer >2 cm
Brullet 1996 (duodenal ulcers) 120 106 (88.3%) 18 (17%) Pre-endoscopic: shock
Endoscopic: ulcer >2 cm
Park 1994∗ 135 127 (94%) 25 (20%) Pre-endoscopic: elevated heart rate, obesity
Endoscopic: location duodenal bulb or lesser curve of
stomach
Choudari 1994 326 308 (94.5%) 44 (14.3%) None (age is the only predictor assessed by the
multivariable analysis)
Villanueva 1993 233 217 (93%) 41 (18.9%) Pre-endoscopic: presence of concurrent illness
Endoscopic: location posterior duodenal bulb, location
superior bulb, ulcer >1 cm
Saeed 1993 80 75 (93.8%) 8 (of 69) (12%) Pre-endoscopic: ≥3 illnesses, life-threatening illness
∗Independent risk factors for surgery (rather than rebleeding).
NSAIDs = nonsteroidal anti-inflammatory drugs.
Table 3. Odds Ratios for Independent Predictors of Rebleeding Based on Multivariable Analyses That Appear in Multiple Clinical Trials
Predictor Study Odds Ratio (95% CI)
Hemodynamic instability Guglielmi et al., 2002 3.68 (1.99–6.81)
Wong et al., 2002 2.21 (1.40–3.48)
Thomopolous et al., 2001 2.31 (1.33–6.97)
Brullet et al., 1996 (duodenal ulcers) 3.53 (1.27–4.10)
Park et al., 1994 NR
Comorbid illness Villanueva et al., 1993 NR
Saeed et al., 1993 Likelihood ratio 7.63, P = 0.005
Active bleeding Guglielmi et al., 2002 14.47 oozing∗, 13.38 spurting∗∗
Wong et al., 2002 1.65 (1.07–2.56)
Chung et al., 2001 6.48 (1.88–22.49)
Thomopolous et al., 2001 2.45 (1.51–3.93)
Brullet et al., 1996 (gastric ulcers) 2.98 (1.12–7.91)
Large ulcer size (≥2 cm) Guglielmi et al., 2002 4.61 (2.20–9.64)
Wong et al., 2002 1.80 (1.15–2.83)
Brullet et al., 1996 (gastric ulcers) 3.64 (1.34–9.89)
Brullet et al., 1996 (duodenal ulcers) 2.29 (1.13–10.9)
Large ulcer size (>1 cm) Villanueva et al., 1993 NR
Posterior duodenal ulcer Thomopolous et al., 2001 2.48 (1.37–7.01)
Villanueva et al., 1993 NR
Lesser gastric curve ulcer Brullet et al., 1996 (gastric ulcers) 2.79 (1.01–7.69)
Park et al., 1994 NR
∗95% CI = 3.27–64.05.
∗∗95% CI = 2.69–66.66.
NR = not reported; CI = confidence intervals; Hg = hemoglobin.
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Table 4. Comparison of Positive and Negative Studies for Each Pre-
dictor of Rebleeding After Endoscopic Therapy That Reached Sta-
tistical Significance in Multivariable Analyses in At Least Two Clin-
ical Trials
No. of Studies No. of Studies
in Which in Which Risk
Predictor Was Factor Did
Independently Not Reach
Predictor Significant Significance
Hemodynamic instability 5 0
Comorbid illness 2 5
Active bleeding 5 3
Large ulcer size 4 1
Posterior duodenal ulcer 2 1
Lesser gastric curvature ulcer 2 0
DISCUSSION
The independent predictors of rebleeding in this systematic
review help identify patients at high risk for recurrent hem-
orrhage after endoscopic therapy for bleeding peptic ulcers.
The independent pre-endoscopic predictors of rebleeding that
are significant in at least two separate studies are hemody-
namic instability and comorbid illness. The independent en-
doscopic predictors of rebleeding that are significant in at
least two separate studies are active bleeding at endoscopy,
large ulcer size, posterior duodenal location, and lesser gas-
tric curve location. Of these, on the basis of consistency and
statistical strength, hemodynamic instability, active bleeding,
large ulcer size, and posterior duodenal location appear to be
Table 5. Proportion of Patients With and Without Independent Predictors Who Experienced Rebleeding After Endoscopic Therapy
% Rebleeding % Rebleeding % Rebleeding
in Patients in Patients in Entire
Predictor Study With Predictor Without Predictor Study Population
Hemodynamic instability Guglielmi et al., 2002 41.1 (30/73) 14.8 (54/366) 20 (86/429)
Wong et al., 2002∗ 19.2 (35/182) 6 (59/946) 8.3 (94/1,128)
Thomopolous et al., 2001∗ 47.1 (24/51) 16 (54/339) 22 (86/390)
Brullet et al., 1996∗ (DU) 32.0 (8/25) 12.3 (10/81) 16.7 (17/102)
Park et al., 1994 NR NR 20 (25/127)
Comorbid illness Villanueva et al., 1993 36.5 (42/115) 12.7 (15/118) 24.5 (57/233)
Saeed et al., 1993 NR NR 12 (8/69)
Active bleeding Guglielmi et al., 2002 20.3 (39/192) 18 (45/247) 20 (86/829)
Wong et al., 2002∗ 12.1 (71/587) 4.2 (23/541) 8.3 (94/1,128)
Chung et al., 2001 NR NR 25.2 (35/139)
Thomopolous et al., 2001∗ 48.9 (46/94) 10.8 (32/296) 22 (86/390)
Brullet et al., 1996∗ (GU) 26 (13/50) 8 (10/125) 13.1 (23/175)
Large ulcer size (≥2 cm) Guglielmi et al., 2002 31.3 (40/128) 14.1 (44/311) 20 (86/429)
Wong et al., 2002∗ 14.8 (36/244) 6.6 (58/884) 8.3 (94/1,128)
Brullet et al., 1996∗ (GU) 23.9 (16/67) 6.5 (7/108) 13.1 (23/175)
Brullet et al., 1996∗ (DU) 36.3 (8/22) 12 (10/84) 16.7 (17/102)
Large ulcer size (>1 cm) Villanueva et al., 1993 42.0 (34/81) 15.1 (23/152) 24.5 (57/233)
Posterior duodenal ulcer Thomopolous et al., 2001∗ 43.2 (16/37) 17.6 (62/353) 22 (86/390)
Park et al., 1994 44 (11/25) 13.7 (14/102) 20 (25/127)
Villanueva et al., 1993 57.1 (20/35) 18.7 (37/198) 24.5 (57/233)
Lesser gastric curve ulcer Brullet et al., 1996∗ (GU) 22.9 (16/70) 6.7 (7/105) 13.1 (23/175)
Park et al., 1994 35 (7/20) 16.8 (18/107) 20 (25/127)
∗Percentage of patients experiencing rebleeding was not available. Percentage of patients experiencing overall failure (defined as the failure to achieve initial hemostasis and recurrent
hemorrhage) is reported.
NR = not reported; DU = duodenal ulcer; GU = gastric ulcer.
the most important predictors of rebleeding. The presence of
these factors merits clinical concern and consideration of a
more aggressive post-hemostasis care strategy.
An area of particular interest is the use of second-look en-
doscopy after the initial control of hemorrhage. This strategy
has been shown to modestly decrease the risk of rebleed-
ing (24), but remains controversial due to conflicting data
(25), high costs, and the fact that published studies did not
employ intensive IV PPI therapy after endoscopic hemosta-
sis. Given the relatively low risk of rebleeding after therapy,
a policy of routine second-look endoscopy would lead to a
large number of unnecessary procedures. On this basis, the
international Nonvariceal UGI Bleeding Consensus Group
in 2003 concluded that second-look endoscopy would be of
statistical benefit only in select high-risk patients, although
this patient subset is not clearly defined (26). Performing risk
stratification based on information available after the index
endoscopy could select patients that are most likely to bene-
fit from second-look endoscopy, improving clinical outcomes
while limiting costs. Prospective clinical trials are necessary
to determine if the risk factors identified in this systematic
review can select patients most likely to benefit from second-
look endoscopy.
Another matter of interest is the intensive care unit (ICU)
observation of patients with UGIB, an area of limited clin-
ical research (27, 28). Experts have recommended that pa-
tients with high-risk peptic ulcers should be monitored in
the ICU after endoscopic therapy (29). The large majority of
these patients, however, will not suffer rebleeding. Identifi-
cation of patients at particularly high risk for rebleeding and
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Table 6. Factors Not Independently Predictive of Rebleeding After
Endoscopic Therapy in More than One Study
No. of Studies
No. of Studies in Which





NSAID use 6 1
Anticoagulation 1 0
Smoking 2 0
EtOH abuse 2 0
Hx PUD 4 1
Hematemesis 4 0
Hemoglobin <10 g/dL 2 1
Transfusion requirement 2 0
(pre-endoscopy)
Esoph lesion 2 0
DU (vs GU) 4 0
Fundic ulcer 2 1
Incisura ulcer 2 0
Antral ulcer 3 0
Pyloric ulcer 3 0
Ant duod ulcer 3 0
Sup duod ulcer 2 0
Inf duod ulcer 2 0
Anastamotic ulcer 1 0
Stoma ulcer 2 0
Volume of epi injection 2 0
PUD = peptic ulcer disease; DU = duodenal ulcer; GU = gastric ulcer; esoph =
esophageal; duod = duodenal; ant = anterior; sup = superior; inf = inferior; epi =
epinephrine; EtOH = alcohol; Hx = history.
subsequent appropriate triage to the ICU is likely to improve
clinical outcomes. Prospective data will also be necessary to
determine if the abovementioned risk factors can identify pa-
tients most likely to benefit from ICU observation, potentially
in combination with second-look endoscopy.
These predictors might also be useful in determining
the necessity of high-dose IV PPI therapy after endoscopic
hemostasis. The current data support the use of IV bolus
plus continuous infusion PPI in patients receiving endoscopic
therapy for high-risk bleeding ulcers (30–36), with decisions
based solely on endoscopic criteria (active bleeding, non-
bleeding visible vessel, and adherent clot). Future studies
may be useful in determining whether predictive factors can
identify certain patients that derive a greater benefit (or in-
versely are unlikely to derive additional benefit) from the use
of bolus plus continuous infusion of PPIs after endoscopic
therapy. However, because continuous infusion PPI therapy
has become the standard therapy and will presumably be used
in future studies of ulcer rebleeding after endoscopic therapy,
such an assessment may be difficult to perform.
The studies included in this systematic review evaluated
patients with high-risk bleeding ulcers requiring endoscopic
hemostatic therapy. The current evidence supports hospital
admission for all such patients (37, 38). There are limited
data, however, that do suggest that outpatient management of
selected patients with nonbleeding visible vessels and favor-
able prognostic indicators may be safe and cost-effective (39),
and a recent study demonstrated that very frequent oral PPI
therapy achieves pH control similar to continuous IV infusion
(40). Therefore, a set of predictors that could reliably identify
patients with a risk of rebleeding near zero after endoscopic
treatment (and oral PPI therapy) could allow for the outpa-
tient management of certain patients, potentially conserving
valuable resources.
Although substantial data have been published on the topic
of risk stratification in UGIB, evidence-based guidelines for
managing patients after initial hemostasis do not exist. This
systematic review serves to identify risk factors for recur-
rent bleeding after endoscopic therapy that can be integrated
and prospectively tested to validate their predictive ability.
Based on such studies, strategies in which these risk factors
are used to guide clinical management can be developed. The
suggested areas of future investigation in UGIB risk stratifi-
cation are: (a) a reappraisal of the predictors of rebleeding in
patients receiving “optimal” medical and endoscopic man-
agement, (b) a prospective validation of a composite scoring
system that contains some or all of the predictors identified in
this systematic review, (c) an evaluation of the clinical benefit
and cost-effectiveness of performing second-look endoscopy
in patients with predictors identified in this systematic review,
(d) an evaluation of the clinical benefit and cost-effectiveness
of ICU observation in patients with predictors identified in
this systematic review, and (e) an evaluation of the role of the
identified predictors in selecting patients for oral PPI therapy
and outpatient management after endoscopic therapy.
This systematic review has several important limitations
that may affect the clinical applicability. First, what is cur-
rently considered as “optimal” medical therapy for high-
risk bleeding ulcers, consisting of IV PPI bolus followed by
continuous infusion, was not delivered in any of the com-
ponent clinical trials. The risk factors identified in these
trials might be affected in either a mitigating or an accentu-
ating fashion by high-dose PPI therapy, and as such, a reap-
praisal of these predictors in prospective studies that utilize
current optimal pharmacologic therapy is important. Second,
epinephrine monotherapy, which is documented to be inferior
to epinephrine plus a second modality such as thermal ther-
apy or injection of sclerosant (41), was used in two trials and
in a study arm of a third trial. The predictors from studies
employing “suboptimal” therapy may not be generalizable
to patients receiving standard endoscopic therapy, defined as
epinephrine followed by a second modality. However, we did
note that the independent predictors from the studies employ-
ing epinephrine alone were generally similar to those from the
other studies in which dual endoscopic therapy was applied.
Also, as mentioned, the included studies generally did not
report ORs for negative predictors in the multivariable analy-
sis, preventing the calculation of a comprehensive summary
OR that includes data from both positive and negative stud-
ies for each predictor. Therefore, the reported summary ORs
are likely to be an overestimation of the effect. Moreover,
due to significant disparity among trials regarding design,
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statistical analysis, and end points, a clinical scoring system
could not be devised. While these limitations should be taken
into account when considering the clinical applicability of
this systematic review, we do not believe that they substan-
tially detract from the conclusions, particularly pertaining to
the identification of future areas of research.
In summary, several clinical, laboratory, and endoscopic
factors have been shown to independently predict recurrent
hemorrhage after successful endoscopic treatment of high-
risk bleeding peptic ulcers. The presence of these factors can
identify patients at particularly high risk for rebleeding, a sub-
group that may be most likely to benefit from an aggressive
post-therapy care, including ICU monitoring and scheduled
second-look endoscopy. Prospective studies designed to for-
mally assess the relative utilities of these factors in predicting
rebleeding and dictating management are needed.
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